Back to results
US 2021/0228500 A1Published application
Cellular retinoid binding protein antagonists and uses thereof
AssigneeCase Western Resrve University
InventorsMarcin Bernard GOLCZAK, Josie Ann SILVAROLI
Life of this patent
Estimating the term…
Abstract
A method of treating an ocular, inflammatory, immune, and/or metabolic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound having a structure of formula (I).
Claims19
1:
- A method of treating light induced retinal degeneration in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of a compound having a structure of formula (II):
- or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein:
- R1 and R2 are each independently H, halogen, alkyl, alkylene-alkoxy, hydroxyl, —C(O)-alkyl, or —C(O)O-alkyl, each of which is optionally substituted with R8;
- R3 is alkyl, alkylene, or OH, each of which is optionally substituted with R8;
- R5 and R6 are each independently hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, N(R9)2, alkylene-NH2 alkylene-N(R9)2 or —N(R9)(alkylene-OH), each of which is optionally substituted with R8;
- R8 is halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- R9 is H, halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- R10 is H, halogen, hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, N(R9)2 alkylene-NH2 alkylene-N(R9)2, or —N(R9)(alkylene-OH), each of which is optionally substituted with R8;
- and
- X1 is NH, O, or CH2
- X2, X3, X4, X5 are independently NH, O, CH2 or absent;
- Y1 is N or CH;
- and
- the dashed line is an optional bond.
12 more elements
2-9:
- (canceled)
10:
- The method of claim 1, wherein R1 is H, C1-C6 alkyl, or C1-C6 haloalkyl.
11:
- The method of claim 1, wherein R2 is C1-C6 alkyl, or C1-C6 haloalkyl.
12:
- The method of claim 1, wherein R3 is methyl, ethyl, propyl, methylene, ethylene, propylene, or OH.
13:
- The method of claim 1, wherein R4 is H, methyl, ethyl, or propyl.
14:
- The method of claim 1, wherein R5 and R6 are each independently hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, or N(R9)2.
15:
- (canceled)
16:
- The method of claim 1, wherein the compound has a structure of formula (IV):
17:
- The method of claim 1, wherein the compound has a structure of formula (IV):
18:
- The method of claim 1, wherein the compound does not have a structure of formula (IV) or formula (V):
19:
- The method of claim 1, wherein the compound does not produce psychoactive effects in the subject.
20:
- The method of claim 1, wherein the compound does not bind to and/or interact with cannabinoid receptor 1 and/or 2.
21:
- The method of claim 1, wherein the compound is an antagonist of cellular retinol binding protein 1 (CRBP1).
22:
- The method of claim 1, wherein the compound does not inhibit enzymatic activities of enzymes involved in the regeneration of visual chromophores.
23:
- The method of claim 1, wherein the compound does not inhibit enzymatic activities of enzymes involved in the production of retinoic acid or its geometric isomers.
24:
- The method of claim 1, wherein the compound lowers the concentration of retinaldehyde in retinal tissues.
25:
- The method of claim 1, wherein the compound reduces the formation of A2E and/or retinal dimer in the subject's retina.
26-77:
- (canceled)